Publications

  1. Gao RW, Ma J, Pisansky TM, Kruse JJ, Stish BJ, Kowalchuk RO, McMenomy BP, Waddle MR, Phillips RM, Choo R, Davis BJ. Dosimetric Features of Ultra-Hypofractionated Intensity Modulated Proton Therapy for Prostate Cancer. Int J Part Ther. 2024 Jun; 12:100015 Epub 2024 Apr 24
    View PubMed
  2. Choo R, Hillman DW, Mitchell C, Daniels T, Vargas C, Rwigema JC, Corbin K, Keole S, Vora S, Merrell K, Stish B, Pisansky T, Davis BJ, Amundson A, Wong W. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2023 Apr 1; 115 (5):1085-1094 Epub 2022 Nov 22
    View PubMed
  3. Laughlin BS, Voss MM, Toesca DAS, Daniels T, Golafshar MA, Keole SR, Wong WW, Rwigema JC, Davis B, Schild SE, Stish BJ, Choo R, Lester S, DeWees TA, Vargas CE. Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical Prostatectomy. Adv Radiat Oncol. 2023 Mar-Apr; 8 (2):101143 Epub 2022 Dec 10
    View PubMed
  4. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU. External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys. 2023 Mar 1; 115 (3):645-653 Epub 2022 Sept 28
    View PubMed
  5. Kowalchuk RO, Kim H, Harmsen WS, Jeans EB, Morris LK, Mullikin TC, Miller RC, Wong WW, Vargas CE, Trifiletti DM, Phillips RM, Choo CR, Davis BJ, Beriwal S, Tendulkar RD, Stish BJ, Breen WG, Waddle MR. Cost effectiveness of treatment strategies for high risk prostate cancer. Cancer. 2022 Nov 1; 128 (21):3815-3823 Epub 2022 Sept 07
    View PubMed
  6. Wong WW, Hillman DW, Daniels TB, Vargas CE, Rwigema JC, Corbin KS, Keole SR, Merrell KW, Stish BJ, Pisansky TM, Davis BJ, Mitchell CM, Choo R. A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life. Prostate. 2022 Oct; 82 (14):1338-1345 Epub 2022 July 05
    View PubMed
  7. Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209. Epub 2022 Jun 02.
    View PubMed
  8. Weishaupt LL, Sayed HK, Mao X, Choo R, Stish BJ, Enger SA, Deufel C. Approaching automated applicator digitization from a new angle: Using sagittal images to improve deep learning accuracy and robustness in high-dose-rate prostate brachytherapy. Brachytherapy. 2022 Jul-Aug; 21 (4):520-531 Epub 2022 Apr 11
    View PubMed
  9. Owens JL, Beketova E, Liu S, Shen Q, Pawar JS, Asberry AM, Yang J, Deng X, Elzey BD, Ratliff TL, Cheng L, Choo R, Citrin DE, Polascik TJ, Wang B, Huang J, Li C, Wan J, Hu CD. Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation. Mol Cancer Ther. 2022 Mar 1; 21 (3):448-459
    View PubMed
  10. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol. 2022 Mar 1; 8 (3):e216871 Epub 2022 Mar 17
    View PubMed
  11. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T. Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer a patient-level data analysis of 3 cohorts. JAMA Oncology. 2022 Mar; 8 (3):e216871
  12. Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in (11)C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Dec 1; 27 (23):6376-6383 Epub 2021 Sept 30
    View PubMed
  13. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open. 2021 Dec 1; 4 (12):e2138550 Epub 2021 Dec 01
    View PubMed
  14. Kowalchuk RO, Hillman D, Daniels TB, Vargas CE, Rwigema JM, Wong WW, Stish BJ, Dueck AC, Choo R. Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer. Clin Transl Radiat Oncol. 2021 Nov; 31:34-41 Epub 2021 Sept 15
    View PubMed
  15. Glicksman R, Loblaw DA, Morton G, Szumacher E, Chung HT, Vesprini D, Chu W, Liu SK, Choo CR, Deabreu A, Mamedov A, Zhang L, Cheung P. Elective Pelvic Nodal Irradiation With A Simultaneous Hypofractionated Integrated Prostate Boost for Localized High Risk Prostate Cancer: Long Term Results From a Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 2021 Nov 1; 111 (3S):S134
    View PubMed
  16. Glicksman RM, Loblaw A, Morton G, Szumacher E, Chung HT, Vesprini D, Chu W, Liu SK, Choo R, Deabreu A, Mamedov A, Zhang L, Cheung P. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. Radiother Oncol. 2021 Oct; 163:21-31 Epub 2021 July 26
    View PubMed
  17. Choo R, Hillman DW, Daniels T, Vargas C, Rwigema JC, Corbin K, Keole S, Vora S, Merrell K, Stish B, Pisansky T, Davis B, Amundson A, Wong W. Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute Toxicity. Int J Part Ther. 2021 Fall; 8 (2):41-50 Epub 2021 Sept 14
    View PubMed
  18. Bryant CM, Henderson RH, Nichols RC, Mendenhall WM, Hoppe BS, Vargas CE, Daniels TB, Choo CR, Parikh RR, Giap H, Slater JD, Vapiwala N, Barrett W, Nanda A, Mishra MV, Choi S, Liao JJ, Mendenhall NP, Genitourinary Subcommittee of the Particle Therapy Co-Operative Group. Consensus Statement on Proton Therapy for Prostate Cancer. Int J Part Ther. 2021 Fall; 8 (2):1-16 Epub 2021 Apr 12
    View PubMed
  19. Gao RW, Tollefson MK, Thompson RH, Potretzke AM, Quevedo FJ, Choo R, Davis BJ, Pisansky TM, Harmsen WS, Stish BJ. Predictors of Locoregional Recurrence and Delineation of Adjuvant Radiation Therapy Fields for Patients With Upper Tract Urothelial Carcinoma Receiving Nephroureterectomy. Pract Radiat Oncol. 2021 Sep-Oct; 11 (5):e468-e476 Epub 2021 Feb 23
    View PubMed
  20. Breen WG, Stish BJ, Harmsen WS, Froemming AT, Mynderse LA, Choo CR, Davis BJ, Pisansky TM. The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer. Radiother Oncol. 2021 Aug; 161:9-15 Epub 2021 May 21
    View PubMed
  21. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol. 2021 Aug; 80 (2):142-146 Epub 2021 May 10
    View PubMed
  22. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, D'Amico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D. Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open. 2021 Jul 1; 4 (7):e2115312 Epub 2021 July 01
    View PubMed
  23. Bai M, Gergelis KR, Sir M, Whitaker TJ, Routman DM, Stish BJ, Davis BJ, Pisansky TM, Choo R. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer. Cancer Med. 2020 Nov; 9 (21):7925-7934 Epub 2020 Sept 15
    View PubMed
  24. Gergelis KR, Kreofsky CR, Choo CS, Viehman J, Harmsen WS, Lester SC, Pisansky TM, Davis BJ, Stish BJ, Choo R. Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. Pract Radiat Oncol. 2020 Sep - Oct; 10 (5):e378-e387 Epub 2020 Feb 26
    View PubMed
  25. Choo R, Nehra A, Zattoni F, Pagliaro LC, Karnes RJ. Is there any benefit in adding postoperative adjuvant concurrent radiotherapy and chemotherapy for penile cancer with regional lymph node metastasis? Minerva Urol Nefrol. 2020 Aug; 72 (4):474-481 Epub 2019 July 25
    View PubMed
  26. Whitaker TJ, Routman DM, Schultz H, Harmsen WS, Corbin KS, Wong WW, Choo R. IMPT versus VMAT for Pelvic Nodal Irradiation in Prostate Cancer: A Dosimetric Comparison. Int J Part Ther. 2019 Winter; 5 (3):11-23 Epub 2019 Mar 21
    View PubMed
  27. Jethwa KR, Hellekson CD, Evans JD, Harmsen WS, Wilhite TJ, Whitaker TJ, Park SS, Choo CR, Stish BJ, Olivier KR, Haloi R, Lowe VJ, Welch BT, Quevedo JF, Mynderse LA, Karnes RJ, Kwon ED, Davis BJ. (11)C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities. Adv Radiat Oncol. 2019 Oct-Dec; 4 (4):659-667 Epub 2019 July 04
    View PubMed
  28. Gergelis KR, Remme DS, Choo CR. Isolated biopsy-proven recurrence of prostate carcinoma in the spermatic cord after radical prostatectomy detected with 11C-Choline PET/CT. Urol Case Rep. 2019 Sep; 26:100985 Epub 2019 July 31
    View PubMed
  29. Merrell KW, Davis BJ, Goulet CC, Furutani KM, Mynderse LA, Harmsen WS, Wilson TM, McLaren RH, Deufel CL, Birckhead BJ, Funk RK, McMenomy BP, Stish BJ, Choo CR. Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. Brachytherapy. 2019 May - Jun; 18 (3):306-312 Epub 2019 Mar 08
    View PubMed
  30. Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ. Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. Adv Radiat Oncol. 2019 Apr-Jun; 4 (2):314-322 Epub 2019 Feb 19
    View PubMed
  31. Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ. Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy. 2019 Jan - Feb; 18 (1):1-7 Epub 2018 Oct 04
    View PubMed
  32. Choo R, Kazemba B, Choo CS, Lester SC, Whitaker T. Proton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes. Int J Part Ther. 2018 Fall; 5 (2):50-57 Epub 2018 Nov 30
    View PubMed
  33. Stish BJ, Davis BJ, Mynderse LA, McLaren RH, Deufel CL, Choo R. Low dose rate prostate brachytherapy. Transl Androl Urol. 2018 Jun; 7 (3):341-356
    View PubMed
  34. Wilhite TJ, Routman D, Arnett AL, Glasgow AE, Habermann EB, Pisansky TM, Boorjian SA, Jethwa KR, Mynderse LA, Roberts KW, Frank I, Choo R, Davis BJ, Stish BJ. Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. Bladder (San Franc). 2018; 5 (3):e34 Epub 2018 Aug 23
    View PubMed
  35. Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, Choo CR, Tzou KS, Bryce AH, Ho TH, Quevedo FJ, Vora SA. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):e969-e975. Epub 2017 Apr 26.
    View PubMed
  36. Westerman ME, Bhindi B, Choo R, Gettman MT, Karnes RJ, Klotz L, Boorjian SA. Media reporting of ProtecT: a disconnect in information dissemination? Prostate Cancer Prostatic Dis. 2017 Dec; 20 (4):401-406 Epub 2017 May 02
    View PubMed
  37. Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R. Brachytherapy in the Management of Prostate Cancer. Surg Oncol Clin N Am. 2017 Jul; 26 (3):491-513 Epub 2017 May 11
    View PubMed
  38. Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED. Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. Eur Urol. 2017 Mar; 71 (3):340-348 Epub 2016 Sept 03
    View PubMed
  39. Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2017 Mar 1; 97 (3):526-535 Epub 2016 Nov 17
    View PubMed
  40. Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016 Nov 10; 34 (32):3864-3871
    View PubMed
  41. Birckhead BJ, Fossum CC, Deufel CL, Furutani KM, Merrell KW, Schueler BA, Mynderse LA, Choo R, Davis BJ. Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by Day 0 fluoroscopy and 4-month postimplant pelvic x-ray. Brachytherapy. 2016 Nov - Dec; 15 (6):714-721 Epub 2016 Aug 16
    View PubMed
  42. Jethwa KR, Furutani KM, Mynderse LA, Wilson TM, Choo R, King BF, Bergstralh E, Davis BJ. Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. J Contemp Brachytherapy. 2016 Oct; 8 (5):371-378 Epub 2016 Nov 04
    View PubMed
  43. Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016 Jul; 70 (1):21-30 Epub 2015 Dec 15
    View PubMed
  44. Mayo CS, Pisansky TM, Petersen IA, Yan ES, Davis BJ, Stafford SL, Garces YI, Miller RC, Martenson JA, Mutter RW, Choo R, Hallemeier CL, Laack NN, Ma DJ, Olivier KR, Keole SR, Fatyga M, Foote RL, Haddock MG. Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Pract Radiat Oncol. 2016 Jul-Aug; 6 (4):e117-e126 Epub 2016 Jan 26
    View PubMed
  45. Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, Danjoux C, Narod SA, Nam RK. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016 Mar 2; 352:i851 Epub 2016 Mar 02
    View PubMed
  46. Chu W, Loblaw DA, Chan K, Morton G, Choo R, Szumacher E, Danjoux C, Pignol JP, Cheung P. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Radiat Oncol. 2015 Apr 18; 10:95
    View PubMed
  47. Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol. 2015; 5:90 Epub 2015 Apr 14
    View PubMed
  48. Ahmed KA, Davis BJ, Mynderse LA, Slezak JM, Bergstralh EJ, Wilson TM, Choo CR. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol. 2014 Jul 29; 9:171 Epub 2014 July 29
    View PubMed
  49. Hallemeier CL, Davis BJ, Pisansky TM, Choo R. Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy. Urol Oncol. 2014 May; 32(4):496-500. Epub 2013 Dec 12.
    View PubMed
  50. Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martinez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley WU, Zietman AL, Efstathiou JA. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014 Mar 1; 88 (3):618-23 Epub 2014 Jan 08
    View PubMed
  51. Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM. Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2014 Jan; 32 (1):24.e1-6 Epub 2013 Mar 11
    View PubMed
  52. Hallemeier CL, Karnes RJ, Pisansky TM, Davis BJ, Gunderson LL, Leibovich BC, Haddock MG, Choo R. Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter. Am J Clin Oncol. 2013 Dec; 36(6):596-600.
    View PubMed
  53. Hallemeier CL, Pisansky TM, Davis BJ, Choo R. Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience. Urol Oncol. 2013 Nov; 31(8):1832-8. Epub 2012 Apr 25.
    View PubMed
  54. Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2013 Apr 1; 85 (5):1239-45 Epub 2012 Dec 19
    View PubMed
  55. Khan L, Choo R, Breen D, Assaad D, Fialkov J, Antonyshyn O, McKenzie D, Woo T, Zhang L, Barnes E. Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol. 2012 Aug; 104(2):263-6. Epub 2012 Jul 31.
    View PubMed
  56. Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Kiss A, Mamedov A, Deabreu A. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 1; 83(2):617-23. Epub 2011 Nov 11.
    View PubMed
  57. Hallemeier CL, Choo R, Davis BJ, Pisansky TM, Gunderson LL, Leibovich BC, Haddock MG. Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012 Apr 1; 82 (5):1938-43 Epub 2011 Apr 20
    View PubMed
  58. Karnes R, Choo C, Call JA. Current Management Approach for Patients with PSA Relapse Following Radical Prostatectomy Interventional Oncology Society Journal.2012;2(1)37-47.
  59. Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity. Int J Radiat Oncol Biol Phys. 2012 Feb 1; 82(2):898-905. Epub 2011 Jan 14.
    View PubMed
  60. Hertzig LL, Choo RC, Lightner DJ, Karnes RJ. Multimodal Treatment Approach to Advanced Female Urethral Squamous Cell Carcinoma Open Journal of Urology. 2012 29 Aug; 2(3):139-43.
  61. Choo CS, Mamedov A, Chung M, Choo R, Kiss A, Danjoux C. Vitamin D insufficiency is common in patients with nonmetastatic prostate cancer. Nutr Res. 2011 Jan; 31(1):21-6.
    View PubMed
  62. Choo R, Quevedo F, Choo CS, Blute M. Can radiotherapy be a viable salvage treatment option for the relapsed seminoma confined to the infra-diaphragm region recurring after primary chemotherapy for bulky stage II seminoma? Can Urol Assoc J. 2010 Oct; 4 (5):E137-40
    View PubMed
  63. Choo R, Long J, Gray R, Morton G, Gardner S, Danjoux C. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer. 2010 Jun; 18(6):715-22. Epub 2009 Jun 09.
    View PubMed
  64. Choo R. Salvage radiotherapy for patients with PSA relapse following radical prostatectomy: issues and challenges. Cancer Res Treat. 2010 Mar; 42 (1):1-11 Epub 2010 Mar 31
    View PubMed
  65. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R. Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors. 2010; 2(4):e65. Epub 2010 Dec 31.
    View PubMed
  66. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys. 2009 Nov 15; 75(4):983-9. Epub 2009 May 04.
    View PubMed
  67. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Int J Radiat Oncol Biol Phys. 2009 Oct 1; 75(2):407-12. Epub 2009 Feb 11.
    View PubMed
  68. Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc. 2008 Dec; 83 (12):1364-72
    View PubMed
  69. Choo R, Pearse M, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):989-95. Epub 2008 Apr 23.
    View PubMed
  70. Pearse M, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw A, Cheung P. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2008 Nov 1; 72(3):792-8. Epub 2008 Aug 15.
    View PubMed
  71. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol. 2008 Oct; 180(4):1438-43; discussion 1443-4. Epub 2008 Aug 16.
    View PubMed
  72. Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys. 2008 Sep 1; 72(1):85-92. Epub 2008 Mar 20.
    View PubMed
  73. Choo R, Pearce A, Danjoux C, Morton G, Deboer G, Szumacher E, Loblaw A, Cheung P. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy. Eur Urol. 2007 Dec; 52(6):1645-50. Epub 2006 Nov 15.
    View PubMed
  74. Schwartz DJ, Sengupta S, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, Mynderse LA, Choo R, Davis BJ. Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys. 2007 Oct 1; 69 (2):411-8
    View PubMed
  75. Choo R, Kawakami J, Siemens R, Davis BJ, Brundage M, Pisansky TM. Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int. 2006 Oct; 98(4):773-6.
    View PubMed
  76. Vieth R, Choo R, Deboer L, Danjoux C, Morton GC, Klotz L. Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer. Am J Ther. 2006 Sep-Oct; 13(5):394-9.
    View PubMed
  77. Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E, Cheung P, Deboer G, Chander S. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2006 May 1; 65(1):78-83. Epub 2006 Mar 24.
    View PubMed
  78. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005 Sep 1; 23(25):6132-8.
    View PubMed
  79. Choo R, Woo T, Assaad D, Antonyshyn O, Barnes EA, McKenzie D, Fialkov J, Breen D, Mamedov A. What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers? Int J Radiat Oncol Biol Phys. 2005 Jul 15; 62(4):1096-9.
    View PubMed
  80. Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys. 2005 Jul 1; 62(3):719-24.
    View PubMed
  81. Cheung P, Sixel K, Morton G, Loblaw DA, Tirona R, Pang G, Choo R, Szumacher E, Deboer G, Pignol JP. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys. 2005 Jun 1; 62(2):418-25.
    View PubMed
  82. Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N, Danjoux C, Klotz L, Morton G, Chander S. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys. 2005 Mar 1; 61(3):736-40.
    View PubMed
  83. Choo R, Morton G, Danjoux C, Hong E, Szumacher E, DeBoer G. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate, carcinoma after surgery. Radiother Oncol. 2005 Feb; 74(2):163-7.
    View PubMed
  84. Choo R, Chander S, Danjoux C, Morton G, Pearse A, DeBoer G, Szumacher E, Loblaw A, Cheung P, Woo T. How are hemoglobin levels affected by androgen suppression in non-metastatic prostate cancer patients? Can J Urol.. 2005; 12: 2547-52.
    View PubMed
  85. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer. 2005; 51(1):32-6.
    View PubMed
  86. Woo TC, Choo R, Chander S. An unusual case of concurrent breast and prostate cancer. Can J Urol. 2004 Oct; 11(5):2390-2.
    View PubMed
  87. Choo R, Klotz L, Deboer G, Danjoux C, Morton GC. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int. 2004 Aug; 94(3):295-8.
    View PubMed
  88. Bagnell S, Choo R, Klotz LH, Chaterjee S. Practice patterns of Canadian urologists in the management of stage I testicular seminoma. Can J Urol. 2004 Apr; 11(2):2194-9.
    View PubMed
  89. Choo R, Do V, Sugar L, Klotz L, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol. 2004 Feb; 11(1):2118-24.
    View PubMed
  90. Choo R, Sugar L, Hong E, Mackenzie K, DeBoer G, Danjoux C, Morton G, Klotz L. Is there a progression of histologic grade from radical prostatectomy to local recurrence in patients with clinically isolated local recurrence following surgery? Can J Urol. 2003 Oct; 10(5):1981-5.
    View PubMed
  91. Yap BK, Choo R, Deboer G, Klotz L, Danjoux C, Morton G. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int. 2003 May; 91(7):613-7.
    View PubMed
  92. Hruby G, Choo R, Jackson M, Warde P, Sandler H. Management preferences following radical inguinal orchidectomy for Stage I testicular seminoma in Australasia. Australas Radiol. 2002 Sep; 46(3):280-4.
    View PubMed
  93. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem. 2002 Sep; 35(6):471-5.
    View PubMed
  94. Do V, Choo R, Deboer G, Herschorn S, Danjoux C, Chen CH, Barak I. Urodynamic findings 3 months after radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma. BJU Int. 2002 Jul; 90(1):62-7.
    View PubMed
  95. Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002 Jun 1; 53(2):269-76.
    View PubMed
  96. Choo R, Do V, Herschorn S, DeBoer G, Danjoux C, Morton G, Cheng CH, Barak I, Preiner J. Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002 Jun 1; 53(2):290-6.
    View PubMed
  97. Klotz LH, Choo R, Morton G, Danjoux C. Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can J Urol. 2002 Jun; 9 Suppl 1:2-7.
    View PubMed
  98. Do V, Choo R, De Boer G, Klotz L, Danjoux C, Morton G, Szumacher E, Fleshner N, Bunting P. The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int. 2002 May; 89(7):703-9.
    View PubMed
  99. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002 Apr; 167(4):1664-9.
    View PubMed
  100. Choo R, Sandler H, Warde P, Hruby G, DeBoer G. Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol. 2002 Apr; 9(2):1479-85.
    View PubMed
  101. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C, Morton G, Klotz L, Bhak E, Flavin A. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys. 2002 Mar 1; 52(3):674-80.
    View PubMed
  102. Lock M, Loblaw DA, Choo R, Imrie K. Disseminated intravascular coagulation and PC-SPES: a case report and literature review. Can J Urol. 2001 Aug; 8(4):1326-9.
    View PubMed
  103. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001 Jul 1; 50(3):615-20.
    View PubMed
  104. Hruby G, Choo R, Klotz L, Danjoux C, Murphy J, Deboer G, Morton G, Rakovitch E, Szumacher E, Fleshner N. The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer. BJU Int. 2001 May; 87(7):643-7.
    View PubMed
  105. Hruby G, Choo R, Lehman M, Herschorn S, Kapusta L. Female clear cell adenocarcinoma arising within a urethral diverticulum. Can J Urol. 2000 Dec; 7(6):1160-3.
    View PubMed
  106. Choo CR, Danjoux C, Morton G. Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist's view. Can J Urol. 2000; 7:1043-50.
    View PubMed
  107. MacKenzie R, Balogh J, Choo R, Franssen E. Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1999 Oct 1; 45(3):589-95.
    View PubMed
  108. Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol. 1999 May; 161(5):1521-4.
    View PubMed
  109. Flavin A, Choo R, Franssen E, Danjoux C, Morton G. Pathological T3 and/or margin positive prostate adenocarcinoma with undetectable postoperative PSA - to irradiate or not?: analysis of freedom from PSA failure. Can J Urol. 1998 Jun; 5(2):544-550.
    View PubMed
  110. Choo R, Flavin A, Danjoux CE, Klotz LH. Can radiotherapy salvage isolated local recurrence following radical prostatectomy? Can J Urol. 1997 Sep; 4(3):395-399.
    View PubMed
  111. Choo R, Grimard L, Esche B, Crook J, Genest P, Odell P. Brachytherapy of neck metastases. J Otolaryngol. 1993 Feb; 22(1):54-7.
    View PubMed
  112. Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer. 1991 Nov 15; 68(10):2120-4.
    View PubMed